Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Verona Pharma replaces CFO Lowe with Bungay

Thu, 05th Sep 2013 08:15

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect.Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover. Lowe joined Verona in 2006 and is based in Canada.Bungay is part-time Chief Executive of Chroma Therapeutics and has worked in the biotech and pharma industries for nearly 20 years including a spell as director of corporate communications at Celltech Group.Jan-Anders Karlsson, Chief Executive of Verona Pharma, said: "Richard's experience in financial management of innovative R&D-based businesses as well as his experience in investor relations will be invaluable to Verona Pharma as we move our key clinical programmes forward and grow the Company. "We would like to thank Danny for his significant contributions to Verona Pharma over the last seven years."
More News
9 Jun 2015 14:36

AGM, EGM Calendar - Week Ahead

Read more
9 Jun 2015 05:28

AGM, EGM Calendar - Week Ahead

Read more
8 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
8 Jun 2015 06:49

Verona Pharma Says Study Shows RPL554 Well Tolerated

Read more
8 Jun 2015 05:33

AGM, EGM Calendar - Week Ahead

Read more
5 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
5 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
4 Jun 2015 15:22

AGM, EGM Calendar - Week Ahead

Read more
22 May 2015 13:01

DIRECTOR DEALINGS SUMMARY: Glencore Non-Executive Cuts Stake

Read more
18 May 2015 14:03

DIRECTOR DEALINGS: Verona Pharma Directors Buy Shares

Read more
12 May 2015 16:22

Verona Pharma's loss widens on extended development costs

Verona Pharma posted a widened pre-tax loss for 2014 in the run up to its lead compound's commercial development. The company posted a pre-tax loss of £3.8m for 2014, up from £2.8m a year earlier, as research costs swelled from £1.7m to £2.6m over the period. Development bore a new commercial formu

Read more
12 May 2015 10:30

Verona Loss Widens As It Continues Lead Compound Development

Read more
12 May 2015 05:18

Earnings, Trading Statements Calendar - Week Ahead

Read more
11 May 2015 14:56

Earnings, Trading Statements Calendar - Week Ahead

Read more
11 May 2015 05:34

Earnings, Trading Statements Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.